natgillin/translations-raw huggingface dataset:
This pump is conventional and will therefore not be further described. 
Ova pumpa je konvencionalna 1 stoga ne će biti dalje opisivana.
A cytotoxically active CD3 specific binding construct comprising a first domain specifically binding to human CD3 and an Ig-derived second binding domain, wherein said first domain is deimmunized and comprises a CDR-H1 region comprising an amino acid sequence as depicted in SEQ ID NO: 88, a CDR-H2 region comprising an amino acid sequence as depicted in SEQ ID NO: 90 or 92 and a CDR-H3 region, comprising an amino acid sequence as depicted in SEQ ID NO. 
Citotoksički aktivan specifičan vezujući konstrukt za CD3 koji sadrži prvu domenu koja se specifično veže za ljudski CD3 i drugu vezujuću domenu na bazi Ig-a, pri čemu je prva domena deimunizirana i sadrži CDR-H1 regiju sa sekvencom aminokiselina kako je prikazano u SEQ ID NO: 88, CDR-H2 regiju sa sekvencom aminokiselina kako je prikazano u SEQ ID NO: 90 ili 92 i CDR-H3 regiju sa sekvencom aminokiselina kako je prikazano u SEQ ID NO.
centrifuging the heated cell lysate, wherein a supernatant comprising the AvPAL variant is retained; 
(c) centrifugiranju zagrijanog staničnog lizata, uz zadržavanje supernatanta koji sadrži varijantu AvPAL,;
A process for the preparation of iomeprol according to claim 11 wherein, within the compounds of formula from (1) to (5), R and R' both represent a CONH-CH2(CHOH)CH2OH group, R4 is methyl and R5 is hydrogen. 
Postupak prema zahtjevima 10 ili 11 naznačen time da je za pripremanje spoja s formulom (5) pri čemu oba R i R' predstavljaju skupinu -CONH-CH>-CH(OH)CPLOH, R, je metil i Rs je vodik.
R2b and R2c are independently selected from the group consisting of hydrogen, halogen, C1-C3 alkyl, fluorinated C1-C3 alkyl, cyano, C1-C3 alkoxy, and N(CH3)2; X is selected from the group consisting of 
R2 i R2C su neovisno odabrane iz skupine koju čine vodik, halogen, C;-C3 alkil, fluorirani C,-C3 alkil, cijano, C,-C3 alkoksi i N(CH>),; X je odabrana iz skupine koju čine:
15.The composition of item 14, wherein said functional nucleic acid targets the transcript encoding a protein that contributes to resistance to said drug. 
Pripravak prema zahtjevu 7, gdje ta regulatorna RNA cilja transkripciju koja kodira protein koji doprinosi otpornosti na taj lijek.
The antibody, conjugate or pharmaceutical composition for use according to claim 6 wherein the disease or disorder is a tumor-related disease, wherein the tumor-related disease preferably is selected from the group consisting of breast cancer, gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, colorectal cancer, hepatic cancer, head-neck cancer, cancer of the gallbladder, and the metastases thereof. 
Protutijelo, konjugat ili farmaceutski sastav za uporabu u skladu s patentnim zahtjevom 10 pri čemu je bolest ili poremećaj bolest povezana s tumorom, pri čemu je bolest povezana s tumorom poželjno odabrana iz grupe koja se sastoji od karcinoma dojke, karcinoma želuca, karcinoma jednjaka, karcinoma gušterače, karcinoma pluća, karcinoma jajnika, karcinoma debelog crijeva, kolorektalnog karcinoma, karcinoma jetre, karcinoma glave i vrata, karcinoma žučnog mjehura i njihovih metastaza.
The method of claim 1, the prodrug compound is represented by a structure of Formula 5 or stereoisomer thereof or pharmaceutically acceptable salt thereof 
RH I s u NE s k s 1, tvar sadrži strukturu Formule 5 ili njen stereoizomer ili njenu farmaceutski
The reaction mixture was cooled to room temperature and filtered through hyflow bed to separate the catalyst. 
Reakcijska mješavina je ohlađena na sobnu tempcraturu te profiltrirana kroz hyflow podlogu da sc ukloni katalizator.
The method of claim 13 where the cells are selected from the group consisting of BSC cells, LLC-MK cells, CV-1 cells, COS cells, VERO cells, MDBK cells, MDCK cells, CRFK cells, RAF cells, RK cells, TCMK-1 cells, LLCPK cells, PK15 cells, LLC-RK cells, MDOK cells, BHK-21 cells, CHO cells, NS-1 cells, MRC-5 cells, WI-38 cells, BHK cells, 293 cells, and RK cells. 
Postupak u skladu s patentnim zahtjevom 1 ili 2, naznačen time što su stanice sisavačke stanice, primjerice stanice BSC, stanice LLC-MK, stanice CV-I, stanice COS, stanice VERO, stanice MDBK, stanice MDCK, stanice CRFEK, stanice RAF, stanice RK, stanice TCMK-I, stanice LLCPK, stanice PK15, stanice LLC-RK, stanice MDOK, stanice BHK-21, stanice CHO, stanice NS-1, stanice MRC-5, stanice WI-38, stanice BHK, stanice 293 ili stanice RK.
a tool plug for connecting the adjusting tool system to the secondary unit; 
alatni utikač (31) za spajanje prilagodnog alatnog sustava (3) sa sekundarnom jedinicom (2);
Such a closure or plunger is preferably adapted so that a vial or syringe provided with such a closure or plunger may be used in a process in which the point of a hollow needle is passed through the closure part or plunger so that the point is within the vial, a fluid contents material such as a drug or vaccine solution or suspension, or a reconstitution fluid is introduced into the vial or syringe through the needle, the needle is then withdrawn, and the small residual puncture hole left by the needle in the closure or plunger is sealed by heat sealing of the outside of the closure or plunger, e.g. using a focused laser beam. 
Poželjno je da je takav zatvarač ili klip prilagođen tako da se bočica ili šprica, koji su snabdjeveni s takvim zatvaračem ili klipom, mogu koristiti u postupku u kojemu vršak šuplje igle prolazi kroz dio zatvarača ili klipa i to tako da je vršak u bočici, i da se sadržaj fluidnog materijala, takvog kao što je otopina ili suspenzije lijeka ili cjepiva, ili rekonstituirani fluid uvedu u bočicu ili u špricu kroz iglu, pri čemu se igla nakon toga izvuče, a mala preostala probušena rupica, koja je ostala iza igle u zatvaraču ili u klipu, se nepropusno zatvori pomoću vrućeg nepropusnog zatvaranja s vanjske strane zatvarača ili klipa, na primjer, korištenjem fokusiranog laserskog snopa.
Flocculated filler particle suspension, characterized in that the filler particles have a mono-modal particle size distribution and a volume defined particle size polydispersity expressed as full width at half maximum height (FWHM) of less than 40 µm and a volume determined median particle size (d 50) in the range from 5 to 50 µm, wherein the filler particles comprise a calcium carbonate-comprising material. 
Suspenzija flokuliranih čestica punila, naznačena time što čestice punila imaju jednomodnu raspodjelu veličine čestica i volumno definiranu polidisperznost veličine čestica izraženu kao punu širinu kod polumaksimalne visine (FWHM) od manje od 40 um i volumno određenu srednju veličinu čestica (dso) u rasponu od 5 do 50 um, gdje čestice punila sadrže materijal koji sadrži kalcijev karbonat.
Accordingly, in another embodiment the external column is sterilized after performing step (d). 
Sukladno tomu, u dragoj izvedbi, vanjska kolona se sterilizira nakon provođenja koraka (d).
is selected from the group consisting of hydrogen, alkyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heterocycle, heteroarylalkyl, and (NRCRD)sulfonyl; and RC and RD are independently selected from the group consisting of hydrogen and alkyl. The compound for use of claim 1 or 2, wherein the compound of Formula (I) is 
R4 je odabran iz skupine koja se sastoji od vodika, alkila, arilalkila, cikloalkila, cikloalkilalkila, heterocikla, heteroarilalkila i (NRcRp)sulfonila; i Rc i Rp su neovisno odabrani iz skupine koja se sastoji od vodika 1 alkila, Spoj za uporabu prema patentnom zahtjevu 1 ili 2, naznačen time, da je spoj Formule (I) 2-(2-metilpirolidin-2-il)-1H-benzoimidazol-4-karboksamid;
WO 01/60805 (SmithKline Beecham plc), discloses a novel class of pyrimidinone compounds, inter alia those substituted at N1 and containing a sulphur atom. 
WO 01/60805 (SmithKline Beecham ple), otkriva novu klasu pirimidinonskih spojeva, među ostalim onih supstituiranih na N1i koji sadržavaju atom sumpora.
A lentiviral vector particle according to any one of claims 1-9, or the composition of claim 10, for use in inducing an antigen-specific immune response, optionally a humoral response and/or cellular response. 
Pseudotipizirana čestica lentiviralnog vektora ili pripravak za uporabu prema zahtjevu 14 za induciranje antigen-specifičnog imunološkog odgovora, izborno humoralnog odgovora i/ili celularnog odgovora, ili za liječenje tumora.
The pharmaceutical composition of any one of claims 2 to 4, wherein the pharmaceutical composition is to be administered intravenously. 
Farmaceutska kompozicija patentnog zahtjeva 3, gdje je farmaceutska kompozicija pogodna za intravensku administraciju.
The virus composition of any of the preceding claims, wherein the live, attenuated viruses are selected from the group consisting of Flavivirus, Togavirus, Coronavirus, Rhabdovirus, Filovirus, Paramyxovirus, Orthomyxovirus, Bunyavirus, Arenavirus, Retrovirus, Hepadnavirus, Herpesvirus, Poxvirus families and combinations thereof, preferably, the live, attenuated viruses are Flaviviruses. 
Pripravak u skladu s patentnim zahtjevom 1, naznačen time što žive, oslabljene viruse se bira iz skupine koju čine porodice Flavivirus, Togavirus, Coronavirus, Rhabdovirus, Filovirus, Paramyxovirus, Orthomyxovirus, Bunyavirus, Arenavirus, Retrovirus, Hepadnavirus, Herpesvirus, Poxvirus i njihove kombinacije.
The composition of claim 1 which is in the form of a transdermal patch, ointment, lotion, cream, or gel. 
Pripravak za uporabu prema zahtjevu 1, naznačen time da je u obliku transdermalnog flastera, masti, losiona, kreme ili gela.
The thermal dissipation system of any of the preceding claims, wherein the operational heat emitting components of the vehicle are a motor and a battery pack. 
Sustav za toplinsku disipaciju prema zahtjevu 1, naznačen time da su komponente koje emitiraju radnu toplinu vozila motor i komplet baterija.
The antisense oligonucleotide according to claim 10, wherein said nucleotide analogues are sugar modified nucleotides independently or dependently selected from the group consisting of 2'-O-alkyl-RNA units, 2'-OMe-RNA units, 2'-amino-DNA units, and 2'-fluoro-DNA units. 
Antisens oligonukleotid u skladu s patentnim zahtjevom 10, naznačen time što su navedeni nukleotidni analozi nukleotidi modifikovani šećerom nezavisno ili zavisno odabrani iz grupe koja se sastoji od 2'-O-alkil-RNK jedinica, 2'-OMe-RNK jedinica, 2'-amino-DNK jedinica, i 2'-fluoro-DNK jedinica.
Mice display a tonic extension and/or a tonic flexion of limbs and body followed by clonies of 15-20 sec duration. 
Miševi imaju toničke ekstenzije i/ili toničke fleksije udova i tijela nakon čega slijedi klonička faza u trajanju od 10-20 s.
The assembly consisting of resistor 342 and capacitor 340 forms a low-pass filter for the voltage at the output 90u of amplifier 90, thereby maintaining at the collector of transistor 370 a DC voltage equal to half of the second supply voltage. 
Spoj otpornika 342 i kondenzatora 340 čini niskopropusni filter na izlazu 90u pojačala 90, i tako održava na kolektoru tranzistora 370 istosmjerni napon jednak polovini drugog napona napajanja.
Hence, a bispecific IgG antibody according to the present invention preferably contains one arm that specifically recognizes CD3e. 
Bispecifično IgG protutijelo sukladno patentnom zahtjevu 1, naznačeno time, što navedeno protutijelo specifično prepoznaje CD3€.
The compound for use in a method of treatment according to claim 15 or the use of claim 16, further comprising administering to the subject an additional therapeutic agent, optionally wherein the additional therapeutic agent is administered to the subject concurrently with the compound. 
Spoj za uporabu u postupku liječenja prema zahtjevu 8 ili uporaba prema zahtjevu 9, naznačen(a) time, da nadalje obuhvaća davanje dodatnog terapeutskog sredstva pojedincu, pri čemu je opcijski dodatno terapeutsko sredstvo neki drugi inhibitor Raf-kinaze ili je inhibitor za sljedeće: MEK, mTOR, HSP90, AKT, PI3K, CDK9, PAK, C-kinaza proteina, MAP-kinaza, MAPK-kinaza ili ERK, te se dodatno terapeutsko sredstvo daje pojedincu istovremeno sa spojem.
The compound of claim 1, wherein the R3 group is selected from the group consisting of H, methyl, and trifluoromethyl. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što se skupinu R; bira iz skupine koju čine H, metil, te trifluormetil.
wherein the maximum transverse dimension of the transfer channel (13) is from 1.0 to 3.0 mm; wherein the transfer channel (13) has a length of 3 to 20 mm. 
Uređaj za sprej za nos sukladno Zahtjevu 1, pri čemu je maksimalna transverzalna dimenzija prijenosnog kanala (13) veća od promjera ispusnog otvora (19).
A compressible product in a compressed state packaged in the polymeric machine direction oriented (MDO) film as defined in claim 1 which encloses at least part of the compressible product, wherein at least two parts of the MDO film are sealed and characterised in that the seal has a seal elongation at failure of about 20% to about 100%, as measured in accordance with ASTM F88/F88M-09. The packaged product according to claim 19, wherein the seal has a seal elongation at failure of about 25% to about 100%, as measured in accordance with ASTM F88/F88M-09. The packaged product according to claim 19, wherein the sealing comprises heat sealing. 
Pakirani proizvod u skladu s patentnim zahtjevom 9, ili MDO film u skladu s patentnim zahtjevom 10, naznačen time, da brtva ima elongaciju brtvljenja pri prekidu od oko 25 % do oko 100 %, poželjno brtva ima elongaciju brtvljenja pri prekidu od oko 30 % do oko 90 %, a još je poželjnije da brtva ima elongaciju brtvljenja pri prekidu od oko 35 % do oko 80 %, izmjereno u skladu s ASTM F88/F88M-09. Pakirani proizvod u skladu s patentnim zahtjevom 9 ili 11, ili MDO film u skladu s patentnim zahtjevom 10 ili 11, naznačen time, da brtvljenje podrazumijeva toplinsko brtvljenje, poželjno je da je brtvljenje toplinsko brtvljenje.
The pharmaceutical composition according to any of claims 1 to 6, wherein the selection, number and/or amount of peptides present in the composition is/are tissue, cancer, and/or patient-specific. 
Farmaceutski sastav prema bilo kojem zahtjevu od 1 do 3, gdje je odabir, broj i/ili količina peptida prisutnih u sastavu specifičan za tkivo, karcinom i/ili pacijenta.
obtaining (2530) a context offset used in entropy encoding of the first critical value flag for a current significant coefficient based on the number of previous transformation coefficients having consecutive 1s included in a current subset when the current significant coefficient is not initially entropy-encoded in the current subset and the previous transformation coefficients having consecutive 1s are encoded before the current significant coefficient, according to a scan order of the current subset; and obtaining (2540) a context index indicating a context used in entropy encoding of the first critical value flag by using the context set index and the context offset, 
pribavljanje (2530) kontekstnog pomaka upotrebljavanog u entropijskom dekodiranju indikatora prve kritične vrijednosti na osnovi broja prethodnih koeficijenata transformacije sa slijedećom ls; te pribavljanje (2540) indeksa konteksta koji označava kontekst upotrebljavan u entropijskom dekodiranju indikatora prve kritične vrijednosti upotrebom indeksa skupa konteksta i kontekstnog pomaka,
mono-sulphation of the compound obtained in step d) followed by removal of the O-acyl groups present in compounds IIIa and IIIb obtained in the previous step. 
HR P20190183 T1 ilib u kojoj R 1 R2 jesu kao što je gore definirano; e. - mono-sulfatacija spoja dobivenog u koraku d) nakon čega slijedi uklanjanje O-acilnih skupina prisutnih u spojevima IIIa i IIIb dobivenih u prethodnom koraku.
component A) is a compound of formula I wherein is difluoromethyl; Y is -CHR2- and R2 is isopropyl; or a tautomer of such a compound; and 
Postupak prema zahtjevu 1, naznačen time, da je komponenta A) spoj sa formulom I, pri čemu R1 je difluorometil, Y je -CHR2-, te R2 je izopropil.
In a last aspect, the invention relates to the use of the container according to the present invention to refill a tank or a machine having a refilling opening, said refilling opening presenting means for piercing the tearable membrane of the container and for cooperating with the hopper of the container. 
. Upotreba spremnika u skladu s bilo kojim od patentnih zahtjeva 1 do 14 za ponovno punjenje rezervoara ili stroja s otvorom za ponovno punjenje, naznačena time što navedeni otvor za ponovno punjenje sadrži sredstvo za bušenje pokrova kojeg se može probušiti (7) spremnika i za kooperiranje s lijevkom (5) spremnika, te time što sredstvo za t>&
The dredge tooth in accordance with anyone of claims 1-4, characterized in that at least one wall of the socket (20) is bowed inwardly to define a projection (86) that fits into a trough (84) formed on the base (12). 
Potrošni dio u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je najmanje jedna stijenka (27, 29, 31) šupljine (20) tako ulubljena prema unutra da omeđuje izbočinu koja pristaje u žlijeb načinjen u podnožju (12).
A bifunctional molecule comprising a polypeptide binding partner specific for a given pMHC epitope, and an immune effector polypeptide, the N-terminus of the pMHC binding partner being linked to the C-terminus of the immune effector polypeptide, PROVIDED THAT the said polypeptide binding partner is not a T-cell receptor comprising the alpha chain SEQ ID No: 7 and the beta chain SEQ ID No: 9, and wherein the immune effector polypeptide is a cytokine. 
Bifunkcionalna molekula koja sadrži polipeptidni vezivajući partner specifičan za navedeni pMHC epitop, i imuni efektorni polipeptid, pri čemu je N-terminus pMHC vezivajućeg partnera vezan za C-terminus imunog efektornog polipeptida, UZ UVJET DA navedeni polipeptidni vezivajući partner nije T-stanični receptor koji sadrži alfa lanac SEQ ID No: 7 i beta lanac SEQ ID No: 9, pri čemu pMHC vezivajući partner je heterodimerni aB TCR polipeptidni par, ili jednolančani aB TCR polipeptid, i N-terminus a ili B lanca heterodimernog TCR polipeptidnog para ili N-terminus scTCR polipeptida, je vezan sa C-terminalnom aminokiselinom imunog efektornog polipeptida i pri čemu imuni efektorni polipeptid je antitijelo koje se specifično veže za antigen predstavljen preko T-stanice.
isolating the pure quaternary cyclic ammonium compound; wherein said cyclic tertiary amines and quaternary cyclic quaternary ammonium compounds are compounds of general formula respectively, wherein 
izolaciju čistog kvaternarnog cikličkog amonijskog spoja, pri čemu, navedeni ciklički tercijarni amini i kvaternarna ciklički amonijski spojevi su spojevi opće formule [image] respektivno, gdje R je linearna ili granata C1-C12 alkil skupina;
The solution was filtered and concentrated in vacuo. 
Otopina se filtrira i koncentrira in vacuo.
Mouthwash according to claim 1, characterized in that said hyaluronic acid or salt or complex thereof is in the form of a mixture of sodium and/or potassium hyaluronate of low and high molecular weight. 
Vodica za usta sukladno zahtjevu 1, naznačena time što je hijaluronska kiselina ili sol ili njezin spoj u obliku mješavine natrija i/ili kalija.
selecting hybridomas which produce antibodies specifically binding to the protofibril form of B-amyloid peptide while showing minimal affinity to monomer or dimer forms of B-amyloid peptide. 
odabiru hibridoma koji proizvode protutijela koja se specifično vežu na protofibrilni oblik B-amiloidnog peptida dok pokazuju minimalni afinitet na monomerni ili dimerni oblik B-amiloidnog peptida.
treating or preventing hypoxia resulting from blood loss, anemia, shock, myocardial infarct, stroke or traumatic brain injury; or 
(iv) liječenju ili precenciji hipoksije nastale uslijed gubitka krvi, anemije, šoka, infarkta miokarda, moždanog udara ili traumatske povrede mozga; ili
Use of Lgr5 as a marker for the isolation of tissue or organ stem cells from a tissue or organ sample. 
Uporaba Lgr5 naznačena time da se koristi kao marker za izoliranje matičnih stanica tkiva ili organa iz uzorka tkiva ili organa.
The immunogenic composition of paragraph 33 wherein the additional antigens are antigens derived from a bacterium selected from the group consisting of S.pneumoniae, H.influenzae, N.meningitidis, E.coli, M.cattarhalis, tetanus, diphtheria, pertussis, S.epidermidis, enterococci, S.aureus, and Pseudomonas aeruginosa. 
Imunogeni pripravak u skladu s patentnim zahtjevom 26, naznačen time što su dodatni antigeni antigeni dobiveni iz bakterije koju se bira iz skupine koju čine 5. pneumoniae, H. influenzae, N.meningitidis, E. coli, M. cattarhalis, tetanus, difterija, hripavac, S. epidermidis, enterokoki, S.aureus i Pseudomonas aeruginosa.
A compound according to claim 1, which is an acid addition salt of (E)-3-[1-(4-dimetylaminomethyl-benzenesulfonyl)-1H-pyrroi-3-yl]-N-hydroxy-acrylamide with methanesulphonic acid, or a hydrate thereof. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što je kiselinska adicijska sol (£)-3-[1-(4- dimetilaminometilbenzensulfonil)-1 H-pirol-3-11]-N-hidroksiakrilamida s metansulfonskom kiselinom, ili njegov hidrat.
Additives, such as alkali aluminates and alkali salts, silicates and hydroxides, for example, which additionally increase the pH value of the solution and consequently the reactivity of C5S2$, are particularly preferred and can be metered in an amount ranging from 0.1 to 10% by weight, preferably from 0.5 to 5% by weight, and even more preferably from 1 to 2% by weight. 
Vezivno sredstvo sukladno barem jednom zahtjevu 1 do 6, naznačeno time što vezivno sredstvo sadrži litijeve soli i hidrokside i/ili druge alkalijeve soli i hidrokside i alkalijeve silikate kao dodatke mješavini ili daljnje mješavine, s dodacima mješavini poput alkalijskih soli, silikata 1 hidroksida, koji povećavaju pH vrijednost otopine i posljedično reaktivnost C5S2$, osobito poželjnim.
Stirred over night at room temperature, then 2.4 mmol HCl (2M) was added along with water (3 mL). 
Miješa se preko noći na sobnoj temperaturi, potom se doda 2.4 mmol HCI (2 M) zajedno s vodom HR P20070194 T3 (3 ml).
Referring now to Figures 10 to 12, a container embodying features of a second embodiment is seen generally at 10 in various stages of assembly. 
Pozivajući se sada na slike 10 do 12, karakteristike izvedenog spremnika 10 druge izvedbe iz predmetnog izuma općenito su prikazane u različitim koracima sklapanja.
After the addition was complete, the mixture was allowed to warm to room temperature and stirred for a further six hours. 
Nakon završetka dodavanja, smjesa se ostavi ugrijati na sobnu temperaturu i miješa se daljnjih šest sati.
Product eluted with 20% CH3CN. 
Proizvod je eluiran sa 20% CHLCN.
A delayed release drug formulation according to any of the preceding aspects, wherein the third polymeric material is soluble in water independently of pH. 
Formulacija lijeka s odloženim otpuštanjem sukladno jednom od prethodnih patentnih zahtjeva, naznačeno time, da je pufer fosfatna sol.
Thanks to the presence of the longitudinal notches 54, the necessary deformability of the end section of the staff is guaranteed, which in its turn makes it possible for the raised sections to disengage from the slots, freeing the shaft during the recoil phase in order to allow it to slide. 
Zahvaljujući postojanju uzdužnih ureza 54, zajamčena je potrebna mogućnost deformiranja krajnje sekcije cilindričnog tijela, što zatim omogućava da se uzdignute sekcije oslobode iz utora, oslobađajući cilindrično tijelo za vrijeme faze trzanja s namjerom da se dopusti njegovo klizanje.
k′)—Applying the milling heads to the road surface, with milling dimension Z; 
k ́) - raspodjela glava za glodanje (1g-1t) na površini ceste (FBD), u veličini Z glodanja;
The compound for use according to claim 11, wherein the ammonia-lowering compound is selected from the group consisting of rifaximin, lactulose, ornithine phenylacetate and glycerol phenyl butyrate. 
Spoj za upotrebu prema zahtjevu 11, naznačen time što je spoj koji snižava količinu amonijaka odabran iz skupine koja se sastoji od rifaksimina, laktuloze, ornitin fenilacetata i glicerol feml butirata.